Carolinas HealthCare System

Research and Clinical Trials

Title   Multicenter, Double-blind, Randomized, Parallel-group, Monotherapy, Active-control Study to Determine the Efficacy and Safety of Daclizumab High Yield Process (DAC HYP) vs Avonex® in Patients with Relapsing-Remitting Multiple Sclerosis
Brief Description   The main purpose of the study is to see if the drug DAC HYP (daclizamab) is more effective than Avonex® in the treatment of MS. This study will also allow researchers to learn more about the safety of long-term treatment with DAC HYP in people with MS. The sponsor also wants to see if DAC HYP treatment affects the number and/or size of the MS lesions (abnormal spots) in the
Who may be Eligible   The study is open to men and women ages 18 through 55, who have been diagnosed with Relapsing Remitting MS.
Specialty/Disorder   MS - Multiple Sclerosis
IRB Number   CHS1-10-199
Principal Investigator   Conway, Jill
For More Information, Contact   Rita  M.  Rouse , MA
Phone:  (704) 446-1902  Fax:  (704) 446-6208 
Address:  1010 Edgehill Road North Charlotte, NC 28207
About Carolinas HealthCare System
Who We Are
Community Benefit
Corporate Financial Information
Diversity & Inclusion
Annual Report
Patient Links
Pay Your Bill
Hospital Pre-Registration
Patient Rights
Financial Assistance
Quality & Value Reports
Join Carolinas HealthCare System
Physician Careers

For Employees
Carolinas Connect
Connect with Us
Watch Carolinas HealthCare on YoutubeFollow Carolinas HealthCare on TwitterLike Carolinas HealthCare on FacebookContact Carolinas HealthCareJoin Carolinas HealthCare on LinkedInGo to our mobile website.